Selecta Biotech SE is a European clinical-stage biotechnology company developing a new generation of oligonucleotide therapeutics designed to be safer and more effective.
Our journey began with a simple conviction: precision RNA-targeted medicine can be made both more effective and fundamentally safer. Over more than a decade, we have turned that idea into ESiNAR-X®, our patented platform engineered to act at the molecular source of disease while addressing the safety challenges associated with oligonucleotide therapies. From our first peer-reviewed studies to therapeutic programs now moving toward the clinic, our focus has remained the same: translating our platform into therapeutics that combine precise, sustained activity with a strong safety profile.
A single modular architecture, applied across multiple therapeutic programs with the same scientific rigour.
Our patented platform for designing tailored oligonucleotides that combine high specificity, spontaneous cellular uptake, and excellent tolerability.
Explore
Targeting messenger RNA before a disease-causing protein is produced, interrupting the disease process at its source.
Explore
A precision oligonucleotide therapy designed to offer a new treatment option for patients with therapy-resistant chronic myeloid leukemia.
Explore
A potent oligonucleotide antiviral designed to target conserved viral RNA sequences to disrupt genome integrity and stop viral replication at its source.
ExploreA specific oligonucleotide designed to inhibit a central pathway in renal fibrosis and prevent progression to advanced chronic kidney disease.
Explore
Best MedTech Innovation of the Year 2022 – EU, and a decade of peer-reviewed science behind the platform.
ExploreA team that has taken an idea from rigorous, peer-reviewed science to therapeutic programs now moving toward the clinic.
20+ years of professional experience in oncology, with a biotechnology focus over the last decade.
Coordinates the development and preclinical/clinical validation of therapeutic leads across multiple diseases.
Represents Selecta in intellectual property rights, commercial and medical law.
Leads strategic partnerships and licensing to expand our therapies to new markets.
Selecta Biotech has an authentic company culture built on values that define our identity, our operations and our stakeholder relationships.
We collaborate with regional partners to establish a biotechnology ecosystem supporting interdisciplinary biomedical research.
